Health · Medical Research · 3 hrs ago
Immunotherapy regimen shows long-term survival gains in advanced liver cancer
A treatment called STRIDE has shown long-term survival benefits for people with advanced liver cancer that cannot be removed by surgery.
It starts with one dose of tremelimumab and durvalumab, followed by durvalumab alone.
In the HIMALAYA study, 17.1% of patients were alive after six years, while 19.6% were alive after five years.
The disease can develop silently, and many patients also have cirrhosis, which can affect treatment choices.
For intermediate-stage liver cancer, STRIDE combined with lenvatinib and a procedure to block blood flow to the tumour was linked to a 30% lower risk of disease progression.
The findings point to possible benefits at different stages of liver cancer, but no further next steps are specified.
The STRIDE immunotherapy regimen was linked to long-term survival gains in advanced, inoperable liver cancer.
In the HIMALAYA study, 17.1% of patients were alive at six years, and five-year survival was 19.6%.
STRIDE consists of one dose of tremelimumab and durvalumab, followed by durvalumab alone.
The findings were presented at a media tutorial in Milan organised by AstraZeneca.
The report also said STRIDE combined with lenvatinib and transarterial chemoembolisation may reduce disease progression risk by 30% in intermediate-stage liver cancer.
- Who
- Patients with advanced, inoperable liver cancer.
- What
- The STRIDE immunotherapy regimen was associated with improved long-term survival.
- When
- The findings were reported on October 12, 2026, at a media tutorial held that day.
- Where
- Milan, Italy.
- Why
- To present treatment developments for liver cancer, including long-term outcomes with immunotherapy.
This story does not have two clearly opposing sides.
In the HIMALAYA study, the STRIDE regimen achieved five-year survival of 19.6%; survival at six years reached 17.1%, a figure never previously reported in a phase 3 study at this stage of disease
The STRIDE regimen recorded five-year survival of 19.6%.
Survival with the regimen reached 17.1%.
The findings were discussed at a media tutorial in Milan.
- Regimen
- One dose of tremelimumab and durvalumab, followed by durvalumab alone
- Five-year survival
- 19.6% in the HIMALAYA study
- Six-year survival
- 17.1% in the HIMALAYA study
- Intermediate-stage disease
- STRIDE combined with lenvatinib and transarterial chemoembolisation was reported to reduce progression risk by 30%
Sources
Related news
Pope Leo to have surgery to remove an early-detected lung nodule
Ageing is cancer’s leading risk factor, and care for older adults is limited
Pope Leo XIV to have surgery to remove early-stage lung nodule
Diet and exercise program led to diabetes remission in 54% of trial participants
Nearly 59% of English adults with high blood pressure were unaware, study finds
MASH can cause serious liver damage if not detected and treated early
Imaging Measure May Help Flag Poor Recovery After Successful Stroke Thrombectomy
Patients reported less needle pain while listening to their favorite music
Study warns AI tools often misidentify validated blood pressure monitors
Hyderabad summit discusses advances in knee and hip replacement surgery
Researchers identify proteins that help cancer cells survive chemotherapy
